Effects of the adjuvant MPL+TDM on tumor challenge in the B16 mouse melanoma model

Joseph A. Price, J. Michael C. McGee, Marion R. Patten, Diane Snyder

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Mice were injected three times at 2 week intervals with the adjuvant MPL+TDM or phosphate-buffered saline. Two weeks after the last injection, all mice were challenged subcutaneously with a tumorgenic dose of B16 tumor and observed for 40 days. The adjuvant hastened the time at which tumors appeared (P = 0.02).

Original languageEnglish
Pages (from-to)163-165
Number of pages3
JournalInternational Journal of Immunopharmacology
Volume18
Issue number2
DOIs
Publication statusPublished - 1 Jan 1996

    Fingerprint

Keywords

  • Adjuvant
  • B16
  • Immunotherapy
  • MPL+TDM
  • Tumor
  • Vaccine

Cite this